AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Sunday 25 October 2026
News from the 24 hours to Sunday morning, 25 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by strong Phase III results at ESMO, with Imfinzi combinations lowering the risk of death for patients with bladder cancer and with the small cell form of lung cancer. Smaller stories on a $50 million Abu Dhabi research investment and an AI deal added a mildly positive tone.
What drove it
- ESMO Phase III lung cancer data
- bladder cancer trial results
- Abu Dhabi investment
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Mon 19 Oct | +4.0 | 3 |
| Tue 20 Oct | +5.5 | 24 |
| Wed 21 Oct | +8.7 | 38 |
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
4 stories · 16 headlines · strongest first
Pharma and healthcare on 25 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Imfinzi and Imdelltra cut risk of dying by 58% in lung cancer of the small-cell type +10.08 headlines today · 11 in all · In the Phase III DeLLphi-305 trial, patients given Imfinzi alongside Imdelltra as initial treatment for extensive-stage lung cancer of the small-cell type had a 58% lower risk of death. | ||
| +10.0 | Company announces strong Phase III result for Imfinzi combination. | |
| +10.0 | Phase III result with 58% death risk reduction for Imfinzi. | |
| +10.0 | Imfinzi combination shows strong survival benefit in lung cancer trial. | |
| +10.0 | Pairing cut death risk by 58% in lung cancer (small cell). | |
| +10.0 | Major outlet reports strong survival benefit for combination including Imfinzi. | |
| +10.0 | Unprecedented survival benefit for combination with Imfinzi; Amgen-led release. | |
| +9.2 | Combination extends lung cancer survival. | |
| +8.3 | Huge survival benefit, though credit centres on Amgen's drug. | |
| Imfinzi plus enfortumab vedotin cuts recurrence and death risk in bladder cancer +8.05 headlines today · 8 in all · Perioperative Imfinzi combined with enfortumab vedotin gave a 49% lower risk of recurrence and a 42% lower risk of death for patients with muscle-invasive bladder cancer. | ||
| +10.0 | Company announces strong perioperative bladder cancer trial results. | |
| +10.0 | Perioperative Imfinzi cut recurrence 49% and death 42% in bladder cancer. | |
| +5.8 | Imfinzi bladder combinations positioned against Keytruda; promising but chasing. | |
| +4.2 | AZ pursuing position against Keytruda in bladder cancer; competitive. | |
| +2.5 | Data gathering on Imfinzi in bladder cancer; modestly positive, factual. | |
| AstraZeneca to invest $50m in Abu Dhabi clinical research +5.72 headlines today · AstraZeneca plans a $50 million research investment in Abu Dhabi with Cleveland Clinic Abu Dhabi. | ||
| +5.8 | $50 million clinical trials partnership with Cleveland Clinic Abu Dhabi. | |
| +5.5 | Plans $50 million research investment in Abu Dhabi. | |
| AstraZeneca signs $1.46bn AI deal +6.31 headline today · 4 in all, since 20 October · AstraZeneca has revealed a deal involving AI, and its shares are priced at EUR 153.53. | ||
| +3.3 | AI deal announced; little detail, mildly positive. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.